News
PPBT
0.3999
+8.08%
0.0299
Purple Biotech Granted Nasdaq Compliance Extension
TipRanks · 1d ago
Purple Biotech gets extension to regain compliance with Nasdaq
Purple Biotech gets extension to regain compliance with Nasdaq. The company has until January 21 to regain Compliance with minimum $1.00 bid price requirement. Purple Biotech Ltd (PPBT) has a market value of $8.2 billion. The Nasdaq granted the company an extension of 180 calendar days.
Seeking Alpha · 1d ago
PURPLE BIOTECH RECEIVES EXTENSION TO REGAIN COMPLIANCE WITH THE NASDAQ’S MINIMUM BID PRICE RULE
Reuters · 1d ago
Weekly Report: what happened at PPBT last week (0715-0719)?
Weekly Report · 4d ago
Purple Biotech Eyes Key 2024 Milestones
TipRanks · 07/19 13:18
Weekly Report: what happened at PPBT last week (0708-0712)?
Weekly Report · 07/15 09:40
Purple Biotech Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 07/11 17:34
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
Benzinga · 07/11 17:24
Promising Phase 2 Results for Purple Biotech’s CM24 in Pancreatic Cancer Treatment Bolster Buy Rating
TipRanks · 07/11 16:15
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
Purple Biotech Ltd. Is developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance. The company will hold a virtual key opinion leader (KOL) event on July 11, 2024 at 10:30am ET. Purple Biotech is a clinical-stage company in Israel.
Barchart · 07/10 06:30
Weekly Report: what happened at PPBT last week (0701-0705)?
Weekly Report · 07/08 09:40
Purple Biotech Unveils Incentive for Warrant Holders
TipRanks · 07/02 20:30
Purple Biotech Secures $2 Million From Warrants
TipRanks · 07/02 20:30
Why Purple Biotech (PPBT) Shares Are Trading Lower
Purple Biotech Ltd – ADR (NASDAQ:PPBT) shares are trading lower by 11.5% to $0.37. The company announced the exercise of warrants for $2 million gross proceeds. Purple Biotech has entered into agreements to purchase warrants to purchase American Depositary Shares.
Benzinga · 07/01 18:21
Purple Biotech Secures $2 Million from Warrant Exercise
TipRanks · 07/01 13:32
Purple Biotech Exercises Warrants For $2M Gross Proceeds
Benzinga · 07/01 13:09
Weekly Report: what happened at PPBT last week (0624-0628)?
Weekly Report · 07/01 09:40
Purple Biotech Reveals Encouraging Cancer Study Results
TipRanks · 06/27 12:19
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
Purple Biotech Ltd. Is developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance. Company reports positive interim data from its Phase 2 study of CM24 in combination with Bristol Myers Squibb chemotherapy. Results suggest serum MPO may be a predictive biomarker for survival. The company will host a virtual KOL event on July 11, 2024.
Barchart · 06/27 06:45
Purple Biotech’s 2024 Annual Shareholders Meeting
TipRanks · 06/26 20:57
More
Webull provides a variety of real-time PPBT stock news. You can receive the latest news about Purple Biotech Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.